CYAD-02

Phase 1Biologic

CCelyad Oncology SA

CYAD-02 is one of 54 biologic programs targeting Myelodysplastic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeRecruiting

Myelodysplastic SyndromePhase 1

Recruiting

Competition

Competitive Landscape

61 competitors in Myelodysplastic Syndrome

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

42 2

Neoral

Novartis

Approved

10 3

Exjade

Novartis

Approved

5 4

Cytosar

Teva

Phase 3

41 5

Venclexta

AbbVie

Phase 3

17 6

Fludara

Sanofi

Phase 3

16 7

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

60 8

Danocrine

Rocaltrol

Afinitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2035

Phase 1Recruiting

Myelodysplastic Syndrome

NCT04167696

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting·CCelyad Oncology SA·Phase 1·NCT04167696·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CYAD-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CYAD-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CYAD-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celyad Oncology SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCelyad Oncology SA

CYAD-02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2035

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News